Ophthotech

Ophthotech Therapeutic Pharmaceuticals for Macular Degeneration <![CDATA[5. Combination therapy results in CNV regression]]> image-id:14 <![CDATA[4. E10030 therapy results in stripping of neovascular pericytes from the CNV]]> image-id:13 <![CDATA[3. Lack of significant regression of new blood vessels with Anti-VEGF therapy alone]]> image-id:12 <![CDATA[2. Increased PDGF expression leads to enhanced pericyte coverage of CNV]]> image-id:11 <![CDATA[1. CNV increases PDGF expression]]> image-id:10 <![CDATA[6. ARC1905 inhibits C5-mediated inflammatory and MAC activities]]> image-id:9 <![CDATA[5. VEGF promotes angiogenesis]]> image-id:8 <![CDATA[4. C5a stimulates VEGF and other growth factor production]]> image-id:7 <![CDATA[3. MAC initiates RPE lysis]]> image-id:6 <![CDATA[2. Membrane Attack Complex (MAC)]]> image-id:5